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Multiple sclerosis (MS) is an infl  ammatory, 
demyelinating disease of the central nervous 
system (CNS) believed to be initiated and me-
diated by autoreactive T cells directed against 
myelin antigens (1). It has been hypothesized 
that Th1 cells secreting proinfl  ammatory cyto-
kines including IFN-γ and TNF-α contribute 
to the pathogenesis of MS, whereas Th2 cells 
secreting IL-4, IL-5, and IL-13 ameliorate the 
infl   ammatory process and disease (2). Tran-
scription factors and cell surface molecules 
have been identifi  ed that are tightly associated 
with Th1 or Th2 cells (3, 4). Although it does 
not promote Th1 diff  erentiation, T cell im-
munoglobulin- and mucin domain–contain-
ing molecule (TIM)3 is selectively expressed 
on fully diff  erentiated Th1, but not Th2 cells 
(5). More recently, engagement of TIM3 with 
TIM3 ligand has been shown to regulate both 
the function of Th1 cells and the ability to 
  induce tolerance, as blockade of the TIM3 
pathway accelerates diabetes in the nonobese 
diabetes (NOD) mice model of diabetes and 
prevents the acquisition of transplantation tol-
erance induced by costimulatory blockade (6). 
Furthermore, TIM3-defi  cient mice are refrac-
tory to induction of high dose tolerance in 
  experimental autoimmune encephalomyelitis 
(EAE) (7).
Here, we explored the mechanism for in-
creased IFN-γ secretion by CD4+ T cells in the 
cerebrospinal fl  uid (CSF) of patients with MS, 
postulating that alterations in the TIM3 pathway 
may underlie the enhanced IFN-γ secretion 
observed in patients with the disease. We gen-
erated 104 independent T cell clones from the 
CSF of MS patients and control subjects; cyto-
kine secretion was measured and quantitative 
RT-PCR was used to analyze the specifi  city 
and stability of transcription factors that dictate 
Th1 and Th2 programs. Paradoxically, MS 
CSF clones express higher levels of IFN-γ and 
they express lower levels of messenger RNA 
(mRNA) for both T-bet and TIM3. In vitro 
polarization experiments with CSF clones from 
MS and control subjects demonstrate robust 
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enhancement of IFN-γ secretion, but a relative inability to 
up-regulate TIM3 in MS CSF clones. Using small interfering 
(si)RNA to reduce TIM3 expression on CD4+ T cells and 
IFN-γ secretion when TIM3 expression was inhibited, pro-
viding a mechanistic link between our observations of lower 
TIM3 levels and elevated IFN-γ secretion among MS CSF 
clones. These results are the fi  rst human data to demonstrate 
that TIM3 expression regulates T cell secretion of IFN-γ. 
Moreover, these data suggest that TIM3 may critically regu-
late self-reactive Th1 cells and maintenance of tolerance in 
human autoimmune disease.
RESULTS AND D  I  S  C  U  S  S  I  O  N 
Stability and specifi  city of markers of human Th1 cells
We generated a total of 104 independent CD4+ T cell clones 
from the CSF of patients with MS (n = 6) and control subjects 
(n = 4) and examined their cytokine profi  les using ELISA after 
stimulation with anti-CD3 monoclonal antibody. We selected 
several Th1 and Th2 clones from healthy subjects and exam-
ined mRNA expression levels of Th1- and Th2-associated 
molecules using quantitative RT-PCR. Levels of TIM3 and 
T-bet in T cell clones isolated from control subjects were ex-
pressed at substantially higher levels in Th1 clones, whereas 
GATA-3 was substantially elevated in Th2 cells (Fig. 1 A). 
Levels of STAT1 and STAT4 tended to be higher on Th1 
clones, but the diff  erences were not statistically substantial (Fig. 
1 A and not depicted). We confi  rmed that TIM3 and T-bet are 
diff  erentially expressed on representative Th1 or Th2 clones 
diff  erentiated from PBMCs of healthy subjects (Fig. 1 B).
Figure 1.  Differential expression of T-bet, TIM3, and GATA-3 
among Th1 and Th2 T cell clones. Expression levels of TIM3, T-bet, 
STAT1, and GATA-3 were examined by quantitative RT-PCR. Relative 
  expressions of each transcript have been normalized to a single clone 
expressing the highest level of a transcript. (A) CD4+ T cell clones from the 
CSF of control subjects that secreted >100 pg/ml of IFN-γ and <100 pg/ml 
of IL-13 were defi  ned as Th1 (n = 9), whereas those secreting >100 pg/ml 
of IL-13 and <100 pg/ml of IFN-γ were defi  ned as Th2 (n = 6). 
Error bars represent the standard deviation of mRNA levels among the 
clones. (B) Highly polarized Th1 and Th2 clones were generated from the 
peripheral blood of a healthy normal individual. Levels of TIM3 and T-bet 
transcripts are depicted from representative Th1 and Th2 clones as 
  described in A.
Figure 2.  Cytokine profi  les of CSF clones from MS and control 
subjects. (A) CD4+ T cell clones derived from the CSF of MS patients (n = 72) 
or control subjects (n = 32) were expanded and stimulated with 2.0 μg/ml 
of plate-bound anti-CD3 monoclonal antibody for 2 d. Supernatants 
were collected and IFN-γ and IL-13 were measured by ELISA. Levels of 
cytokine secretion in the absence of stimulation have been subtracted 
from all reported values. T cells from patients with MS secreted signifi  -
cantly higher amounts of IFN-γ (P = 0.033) and comparable amounts of 
IL-13 (P = 0.147) relative to those from control subjects. (B) T cell clones 
derived from both the peripheral blood (PBMC) (n = 23) and CSF (n = 27) 
of three MS patients were expanded and their cytokine profi  les were 
characterized as described in A. CSF clones secreted signifi  cantly greater 
amounts of IFN-γ than did those from peripheral blood (P = 0.009).JEM VOL. 203, June 12, 2006  1415
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Although a subset of CSF-derived T cell clones had highly 
polarized Th1 or Th2 phenotypes, the majority of clones de-
rived from both MS patients and control subjects had a Th0-
like cytokine profi  le, secreting both IFN-γ and IL-13, though 
clones from MS patients secreted higher amounts of IFN-γ 
(P < 0.05) (Fig. 2 A). Furthermore, when comparing clones 
generated from the peripheral blood versus CSF of the same 
patients with MS, CSF clones secreted signifi  cantly  higher 
  levels of IFN-γ (P = 0.009) (Fig. 2 B). These data are consistent 
with previous observations at the mRNA level that MS CSF 
clones more frequently secrete IFN-γ compared with control 
CSF clones than do clones isolated from the peripheral blood 
of the same patients (8, 9), and suggest that Th1 polarization of 
human T cells may be more apparent within the target organ.
Reduced TIM3 expression among MS T cell clones
Despite the fact that clones from patients with MS collec-
tively secreted higher levels of IFN-γ, we found that they 
expressed on average lower levels of transcripts for T-bet and 
TIM3 than did clones from healthy subjects (P < 0.05 for 
both molecules, Fig. 3 A). Though levels of T-bet and TIM3 
were reduced in clones from patients with MS, there was 
nevertheless a strong correlation between transcript levels of 
T-bet and TIM3 in both MS patients and healthy subjects 
(Fig. 3 B). This observation argues against defects in tran-
scriptional regulation of T-bet or TIM3 that are independent 
of one another, and instead suggests that these two molecules 
are coordinately regulated. Because T-bet is a transcription 
factor involved in the transcription of IFN-γ and other Th1 
genes (10), this raises the issue of whether T-bet can directly 
transactivate or indirectly regulate the expression of TIM3.
Impaired induction of TIM3 in MS CSF clones
To directly demonstrate a defect in TIM3 regulation in the 
MS CSF clones, we further polarized clones by repeated 
stimulation in the presence of recombinant IL-12 and anti–
IL-4 monoclonal antibody and measured levels of IFN-γ se-
cretion and TIM3 expression. All clones secreted comparable, 
low amounts of IFN-γ (61.7 ± 22 and 58 ± 28 pg/ml, re-
spectively, for control and MS CSF clones) and after polar-
ization, all secreted substantially higher levels of IFN-γ. 
However, MS CSF T cell clones secreted signifi  cantly higher 
levels of IFN-γ than did those from control subjects, but ex-
pressed lower levels of TIM3 mRNA (P = 0.01) (Fig. 4 A). 
These data directly demonstrate that there is a defect in 
  induction of TIM3 among MS CSF T cell clones.
Given previous reports that TIM3 regulates tolerance (6, 7), 
we hypothesized that the relative inability to up-regulate 
TIM3 on MS CSF clones would render them resistant to tol-
erance mediated by costimulatory blockade. MS and control 
CSF clones were stimulated with anti-CD3 monoclonal an-
tibody in the presence or absence of CTLA-4 Ig to induce 
tolerance. After 7 d of culture, cells were collected and re-
stimulated and production of IFN-γ was measured. Consis-
tent with our hypothesis, MS CSF clones expressing lower 
levels of TIM3 than control clones were resistant to tolerance 
(P = 0.01) (Fig. 4 B).
IFN-γ increases levels of STAT1 mRNA through tran-
scriptional regulation (11) and STAT1 can directly activate 
T-bet in T cells (12), suggesting that levels of IFN-γ should 
correlate with STAT1 signaling and in turn infl  uence levels of 
T-bet expression. We measured levels of STAT1 transcripts 
among CSF clones from patients with MS and healthy con-
trols and found that MS clones expressed signifi  cantly higher 
levels (P = 0.02; unpublished data), consistent with enhanced 
IFN-γ secretion by these clones. To determine if IFN-γ sig-
naling through STAT1 was intact in MS T cell clones, we 
  exposed clones from MS patients and control subjects to re-
combinant IFN-γ and measured levels of total versus acti-
vated, tyrosine-phosphorylated forms of STAT1 protein. 
Consistent with mRNA levels of STAT1, resting levels of to-
tal STAT1 protein were higher in T cell clones from patients 
(Fig. 4 C). Exposure to increasing doses of IFN-γ increased 
levels of phosphorylated STAT1 in MS clones, but remained 
Figure 3.  Altered levels of TIM3, T-bet, and STAT1 among T cell 
clones from MS patients. (A) Expression levels of T-bet and TIM3 were 
examined by quantitative RT-PCR in the panel of CSF-derived T cell clones 
described in Fig. 2 A. Expression levels of each transcript have been nor-
malized to a single clone expressing the highest level of a transcript. 
Clones from MS patients expressed signifi  cantly lower levels of T-bet 
(P = 0.014) and TIM3 (P = 0.029). There were no substantial differences in 
levels of STAT4, TIM1, and GATA-3 (not depicted). Note the greater percentage 
of clones in patients compared with control subjects that secrete high 
amounts of IFN-γ, yet express relatively low levels of TIM3 (bottom right 
regions). (B) Despite differences in levels of T-bet and TIM-3 expression 
between healthy subjects and MS patients, transcript levels were highly 
correlated among all T cell clones (R = 0.9651 and 0.6609, respectively).1416  DYSREGULATED TIM3 EXPRESSION IN AUTOREACTIVE T CELLS | Koguchi et al. 
unchanged in clones from control subjects, perhaps the result 
of an increased sensitivity to IFN-γ signaling in MS clones as 
a result of their higher overall levels of STAT1 protein.
siRNA-mediated reduction of TIM3 enhances T cell 
proliferation and IFN-𝗄 secretion
To provide a mechanistic link between dysregulated TIM3 
expression and IFN-γ secretion in CSF clones from MS 
  patients, we isolated CD4+ T cells from the peripheral blood 
of healthy subjects and used siRNA to reduce expression of 
TIM3 on T cells. The T cells were subsequently stimulated 
with plate-bound anti-CD3/CD28 monoclonal antibodies 
and their proliferative capacity and ability to secrete IFN-γ 
were examined. Inhibition of TIM3 expression on CD4+ T 
cells substantially enhanced proliferation and IFN-γ secretion 
(Fig. 5). We were unable to perform the reciprocal experi-
ment and restore TIM3 expression in the MS CSF clones be-
cause of an inability to transduce the clones with a lentiviral 
vector. These data using ex vivo CD4+ T cells validate the 
physiological relevance of observations made using our large 
panel of CSF-derived T cell clones. Moreover, they directly 
demonstrate that down-modulation of TIM3 expression in 
human CD4+ T cells enhances both IFN-γ secretion and the 
potential for clonal expansion.
Although CSF T cell clones from patients with MS se-
creted higher amounts of IFN-γ than did clones from control 
subjects, they expressed lower levels of mRNA for both 
T-bet and TIM3. These observations were confi  rmed experi-
mentally in vitro. That is, when polarized further under Th1 
conditions that induce T-bet and TIM3 expression, clones 
from control subjects up-regulated TIM3 to much greater 
levels than did T cell clones from patients with MS, despite 
the fact that clones from the MS patients secreted higher lev-
els of IFN-γ. Thus, there is dysregulation of TIM3 expres-
sion among CSF clones from MS patients.
Our data may initially appear paradoxical in that levels of 
T-bet, the master regulator of Th1 cells, are expressed at 
lower levels in MS CSF T cell clones that secrete substantially 
higher levels of IFN-γ, relative to CSF clones from healthy 
subjects. T-bet expression is low but not absent in the MS 
CSF clones; we postulate that the levels of T-bet in the MS 
clones were suffi   cient to allow initial commitment of the 
T cells toward IFN-γ production and that elevated IL-12/
STAT4 signaling in patients with MS (13, 14) compensated 
for reduced T-bet expression to promote elevated IFN-γ se-
cretion in these clones. Consistent with this hypothesis, cul-
ture of MS CSF clones in the presence of IL-12 dramatically 
enhances IFN-γ secretion (Fig. 4 A). Of note is the recent 
report that mice defi  cient for STAT1 are highly susceptible 
to EAE, despite reduced levels of IFN-γ secretion and re-
duced levels of T-bet (15). Thus, reduced levels of T-bet 
do not necessarily predict reduced incidence of EAE or MS 
pathogenicity. It will be important to determine if there are 
additional abnormalities in regulation of proinfl  ammatory 
  cytokine secretion from the CSF T clones that we have isolated 
from MS patients.
In a previous study, it was found that human Th1 lines 
expressed higher levels of TIM-3 mRNA, whereas Th2 
lines expressed higher levels of TIM-1 (16). Moreover, 
analysis of CSF mononuclear cells obtained from MS pa-
tients for mRNA levels of TIM1 and TIM3 indicated that 
higher mRNA expression of TIM-1 was associated with 
clinical remissions and low expression of IFN-γ. However, 
given that TIM3 is expressed by CD4+, CD8+, and CD11b+ 
Figure 4.  Dysregulated TIM3 induction and function among MS 
CSF T cell clones. (A) Relative inability to induce TIM3 expression on MS 
CSF clones. CSF T cell clones from MS patients (n = 5) and healthy subjects 
(n = 6) that secreted comparable levels of IFN-γ (61.7 ± 22 and 58 ± 28 pg/ml, 
respectively, for control and MS CSF clones) were subjected to two 
rounds of Th1 polarization, at which point TIM3 expression and IFN-γ se-
cretion after stimulation were determined. CSF T cells from patients with 
MS secreted signifi  cantly higher amounts of IFN-γ but not TIM3 (P = 0.01), 
demonstrating that they are impaired in their ability to up-regulate TIM3. 
(B) Reduced tolerance induction in MS CSF clones. Control and MS CSF 
clones were stimulated with plate-bound anti-CD3 mAb in the presence/
absence of CTLA-4 Ig to induce tolerance. After 7 d, cells were collected 
and restimulated with anti-CD3 mAb, and supernatants were collected 
after 48 h for measurement of IFN-γ. On average, MS CSF clones expressed 
3.3-fold less TIM3 than did control CSF clones and were resistant to toler-
ance induction (P = 0.01). (C) IFN-γ–mediated STAT1 signaling is func-
tional in MS CSF clones. CSF T cell clones from MS patients and control 
subjects were cultured in the presence or absence of 0.1 or 1 ng/ml of 
recombinant IFN-γ for 3 h, after which time levels of total STAT1 protein 
and active STAT1 protein were determined by ELISA (R&D Systems). Error 
bars represent differences in levels of total or active STAT1 protein among 
three clones examined from MS patients and from healthy subjects.JEM VOL. 203, June 12, 2006  1417
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macrophages (5), all of which can be found in MS CSF fl  uid 
and contribute to the pathogenesis of MS, a major limitation 
of the previous study was analysis of TIM3 and cytokine 
levels using unfractionated CSF mononuclear cells. It was 
unclear which populations of cells expressed TIM3 and the 
detected cytokines, and relative proportions of these popu-
lations likely diff  ered among patients. The present study has 
allowed us to demonstrate that there is dysregulation of 
TIM3 expression and IFN-γ secretion specifi  cally among 
CD4+ T cells from the CSF of MS patients.
TIM3 expression and pathophysiology of MS
In mice, the interaction of TIM3 with TIM3 ligand appears 
to regulate both the function of Th1 cells and the ability to 
induce tolerance (6, 7). In addition, TIM3-defi  cient mice are 
refractory to the induction of high dose tolerance (7). Finally, 
galectin-9 has recently been identifi  ed as a ligand of TIM3 
and has been shown to suppress IFN-γ secretion (17). Our 
data suggest that human TIM3 may similarly play a role in 
the regulation of Th1 cells and maintenance of tolerance in 
the context of MS. Specifi  cally, we demonstrate that reduc-
tion of TIM3 expression on human CD4+ T cells enhances 
both proliferation and IFN-γ secretion after T cell stimula-
tion and that CSF clones from MS patients express lower 
levels of TIM3 than do those from control subjects, yet se-
crete higher levels of IFN-γ. Moreover, T cell clones derived 
from the CSF of patients with MS that express lower levels of 
TIM3 than control clones are resistant to tolerance induction. 
In conclusion, our data indicate that reduced TIM3 expres-
sion may allow uninhibited expansion of IFN-γ–secreting 
cells in the target organ. Indeed, failure to up-regulate T cell 
expression of TIM3 in infl  ammatory sites may represent a 
novel, intrinsic defect that may contribute to the pathogene-
sis of MS and other human autoimmune diseases.
MATERIALS AND METHODS
Subjects. CSF samples were obtained from four control subjects and six MS 
patients with Kurtzke Expanded Disability Status Scale scores between 0 and 2. 
Cerebral spinal fl  uid was drawn from control subjects to rule out encepha-
litis and patients were uniformly negative for any CNS infection or auto-
immune disease. All patients were female and their mean age was 42 yr old 
(range 29–59 yr). No patients had received immunomodulatory drugs or 
corticosteroids within 3 mo before the time at which samples were collected. 
All samples were obtained in compliance with the Brigham and Women’s 
Hospital institutional review board protocol.
Generation of T cell clones. T cell clones were derived from CSF sam-
ples by limiting dilution cloning and mitogenic expansion as we have de-
scribed previously (18). Polarized Th1 and Th2 cells were generated using 
PBMCs from healthy subjects as we have described previously (19). Some 
CSF clones from MS patients and control subjects were further polarized 
  using the same Th1 polarizing conditions.
Proliferation assay and ELISA measurements. T cell clones were stim-
ulated with 2 μg/ml of plate-bound anti-CD3 (clone UCHT1; BD Biosci-
ences) and, after 48 h, supernatants were collected and IFN-γ and IL-13 
cytokine production was determined by ELISA; proliferation was measured 
using a liquid scintillation counter (PerkinElmer) as we have described 
previously (19).
Anergy assay. MS (n = 3) and control (n = 4) CSF clones that on average 
diff  ered in TIM3 expression 3.3-fold were stimulated with plate-bound anti-
CD3 mAb in the presence of CTLA-4 Ig or control Ig and cultured for 7 d, 
at which point T cells were collected, washed, and restimulated with plate-
bound anti-CD3 mAb. Supernatants were collected after 48 h for measure-
ment of IFN-γ by ELISA.
TIM3 siRNA. CD4+ T cells were isolated using the CD4+ T cell isolation 
Kit II (Miltenyi Biotec) from PBMCs. Predesigned siRNA for human TIM3 
and a negative control siRNA were obtained from Ambion. Purifi  ed CD4+ 
T cells (2.5 × 106) were transfected with either negative control siRNA or 
TIM3 siRNA (30 pmol siRNA/transfection) by electroporation, using the 
Nucleofactor Device (Amaxa Inc.). Transfected cells were incubated at 37°C 
for 30 min, followed by addition of 20 U/ml of human IL-2 and transfer of 
the cells to a 96-well plate coated with anti-CD3/CD28 monoclonal anti-
bodies (3 μg/ml and 1 μg/ml, respectively; BD Biosciences). Plates were 
incubated at 37°C for 48 h, at which time IFN-γ secretion and proliferation 
Figure 5.  TIM3 siRNA enhances T cell proliferation and IFN-𝗄 
  secretion. (A) Ex vivo CD4+ T cells were transfected with TIM3 or negative 
control oligonucleotides and TIM3 mRNA levels were determined. After 
transfection, cells were collected and 2.5 × 104 cells/well were stimulated 
in triplicate with plate-bound anti-CD3/CD28 monoclonal antibodies. 
Proliferation measured using tritiated thymidine incorporation (B) and 
IFN-γ secretion (C) were measured after 48 h. Results are representative 
of three independent experiments using blood from three different 
  donors. Similar observations were seen using a second TIM3 siRNA oligo-
nucleotide and when transfecting polarized Th1 cell lines. Thus, RNAi 
inhibition of TIM3 expression induces a CD4 phenotype of the CSF-
  derived MS T cells. Error bars represent the standard deviation 
of triplicate wells in B and C.1418  DYSREGULATED TIM3 EXPRESSION IN AUTOREACTIVE T CELLS | Koguchi et al. 
were determined. Cells from replicate wells were collected for RNA extrac-
tion using TRIzol reagent to assess the extent of down-modulation of TIM3 
(Invitrogen). Reverse transcription was performed using a First Strand 
cDNA Synthesis Kit (Fermentas). Real-time PCR was performed using ABI 
PRISM 7700 Detection System (PerkinElmer).
Quantitative RT-PCR. T cell clones were lysed and total RNA was ex-
tracted using Qiagen Rneasy Mini Kits (QIAGEN). Samples were digested 
with DNase 2 times (QIAGEN RNase-free DNase set and Invitrogen 
  Deoxyribonuclease I Amplifi  cation Grade). Reverse transcription was per-
formed using TaqMan Reverse Transcription Reagent (Applied Biosystems). 
The sequences of primers and probe for TIM3 have been described pre-
viously (16), and those for the housekeeping gene GAPDH were obtained 
commercially (Applied Biosystems). The sequences of primers and probes 
of T-bet, GATA3, STAT1, and STAT4 are available upon request. The 
amount of target RNA in each sample was normalized by fi  rst obtaining the 
∆CT value for each target (the diff  erence in cycle threshold value of the target 
RNA and GAPDH). The relative expression of each target among the clones 
was normalized to an arbitrary maximum value of 1.0 represented by the 
  sample with the lowest ∆CT. All samples were transcribed with and without 
reverse transcriptase to exclude the possibility of genomic contamination.
Statistics. Unpaired Student’s t test was used for all statistical comparisons 
using Prism 4.0 software (GraphPad Software).
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